Nebulized Albuterol Will Not Get NCD Due To Lack Of Data On Patient Subgroups, But Xopenex Loses On Payment Side
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Part B coverage policy for nebulized beta adrenergic agonist therapy for lung disease will continue to be the purview of local Medicare claims contractors.
You may also be interested in...
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.
Sepracor Will Ramp Up Sales Force To Launch NycoMed Drugs
Company will add 200 reps this year to promote Omnaris and Alvesco, as well as existing products like Lunesta.